Neuronetics Inc. (STIM)
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet
The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating Results Conference Call.
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity James Beers - William Blair Danny Stauder - JMP Operator Good day and thank you for standing by. Welcome to the Neuronetics Third Quarter 2024 Financial and Operating Results Conference Call.
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.33 per share a year ago.
STIM Stock Likely to Gain From Updated TMS Coverage
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.
Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.
Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Neuronetics, Inc. (STIM) Q2 2024 Earnings Call Transcript
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Keith Sullivan - President & CEO Steve Furlong - CFO Mark Klausner - IR Conference Call Participants Margaret Andrew - William Blair Adam Maeder - Piper Sandler John Pinney - Canaccord Genuity Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics second quarter 2024 financial and operating results conference call.
Noninvasive Treatment Provider Neuronetics Agrees To Merge With Canadian Firm Greenbrook TMS; Reports Q2 Earnings And Guidance Below Expectations
On Monday, Neuronetics Inc. STIM, a provider of noninvasive treatments for psychiatric disorders, agreed to acquire Greenbrook TMS Inc. GBNHF in an all-stock transaction.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
Neuronetics (STIM) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.17 per share a year ago.
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
